RXi Pharmaceuticals Corp. (RXII) Tops Q2 EPS by 2c

RXi Pharmaceuticals Corp. (NASDAQ: RXII) reported Q2 EPS of ($0.23), $0.02 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $12 thousand versus the consensus estimate of $50 thousand.

For earnings history and earnings-related data on RXi Pharmaceuticals Corp. (RXII) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• RBC cuts Northrop Grumman rating on slower growth, cautious defense outlook
• Investing.com’s stocks of the week